Advanced immunological assessment requires interpretation of serological markers, autoantibody panels, and immunoglobulin levels within clinical context. Antinuclear antibody (ANA) testing serves as a screening tool for systemic autoimmune diseases, with specific antibody patterns (anti-dsDNA for SLE, anti-Smith for SLE, anti-Scl-70 for scleroderma, anti-Jo-1 for polymyositis) providing diagnostic specificity. Immunosuppressive pharmacotherapy follows a hierarchy from corticosteroids (rapid anti-inflammatory effect through NF-kB inhibition) to disease-modifying agents (methotrexate inhibiting dihydrofolate reductase, azathioprine inhibiting purine synthesis) to biologics targeting specific cytokines (TNF-alpha inhibitors, IL-6 receptor antagonists). The clinician must balance immunosuppression efficacy against infection risk, monitoring CBC, hepatic function, and screening for latent tuberculosis before initiating biologic therapy.